• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用iATT算法定量肝脏脂肪含量:与受控衰减参数的相关性

Quantification of Liver Fat Content with the iATT Algorithm: Correlation with Controlled Attenuation Parameter.

作者信息

Ferraioli Giovanna, Raimondi Ambra, Maiocchi Laura, De Silvestri Annalisa, Filice Carlo

机构信息

Dipartimento di Scienze Clinico-Chirurgiche, Diagnostiche e Pediatriche, Università di Pavia, Viale Brambilla 74, 27100 Pavia, Italy.

Dipartimento di Scienze Mediche e Malattie Infettive, Fondazione IRCCS Policlinico San Matteo, Viale Camillo Golgi 19, 27100 Pavia, Italy.

出版信息

Diagnostics (Basel). 2022 Jul 23;12(8):1787. doi: 10.3390/diagnostics12081787.

DOI:10.3390/diagnostics12081787
PMID:35892497
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9394249/
Abstract

Background: The primary aim of our study was to assess the correlation between an improved version of the attenuation coefficient available on the Arietta 850 ultrasound system (iATT, Fujifilm Healthcare, Tokyo, Japan) and controlled attenuation parameter (CAP). The secondary aim was to assess whether focusing only on iATT acquisition without following the strict protocol for liver stiffness measurements would affect iATT measurement. Methods: Consecutive individuals were enrolled. Pearson’s r was used to test the correlation between ATT and CAP values. The concordance between iATT and CAP was tested using Lin’s concordance correlation coefficient (CCC). Results: 354 individuals (203 males, 151 females) were studied. The overall Pearson correlation between CAP and iATT values obtained following or not following the liver stiffness measurement protocol, respectively, were r = 0.73 and r = 0.71. The correlation was affected by the interquartile range/median (IQR/M) of the 10 measurements: it was r = 0.75 for IQR/M ≤ 15% and r = 0.60 for IQR/M > 15%. CCC showed that there was a moderate to good concordance between iATT and CAP values. Conclusion: iATT shows a strong correlation with CAP that does not decrease when the protocol for liver stiffness acquisition is not followed. The correlation between iATT and CAP values is higher when the IQR/M ≤ 15%.

摘要

背景

我们研究的主要目的是评估Arietta 850超声系统(日本东京富士胶片医疗保健公司的iATT)上可用的改进版衰减系数与受控衰减参数(CAP)之间的相关性。次要目的是评估仅专注于iATT采集而不遵循肝脏硬度测量的严格方案是否会影响iATT测量。方法:纳入连续的个体。使用Pearson相关系数r来检验ATT与CAP值之间的相关性。使用Lin一致性相关系数(CCC)来检验iATT与CAP之间的一致性。结果:研究了354名个体(203名男性,151名女性)。分别遵循或不遵循肝脏硬度测量方案获得的CAP与iATT值之间的总体Pearson相关性分别为r = 0.73和r = 0.71。相关性受10次测量的四分位数间距/中位数(IQR/M)影响:IQR/M≤15%时r = 0.75,IQR/M>15%时r = 0.60。CCC表明iATT与CAP值之间存在中度至良好的一致性。结论:iATT与CAP显示出很强的相关性,在不遵循肝脏硬度采集方案时不会降低。当IQR/M≤15%时,iATT与CAP值之间的相关性更高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/870c/9394249/11a103eaba9e/diagnostics-12-01787-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/870c/9394249/6e11a2d49ee9/diagnostics-12-01787-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/870c/9394249/1c69967c0d51/diagnostics-12-01787-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/870c/9394249/3d3b9dba0037/diagnostics-12-01787-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/870c/9394249/11a103eaba9e/diagnostics-12-01787-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/870c/9394249/6e11a2d49ee9/diagnostics-12-01787-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/870c/9394249/1c69967c0d51/diagnostics-12-01787-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/870c/9394249/3d3b9dba0037/diagnostics-12-01787-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/870c/9394249/11a103eaba9e/diagnostics-12-01787-g004.jpg

相似文献

1
Quantification of Liver Fat Content with the iATT Algorithm: Correlation with Controlled Attenuation Parameter.使用iATT算法定量肝脏脂肪含量:与受控衰减参数的相关性
Diagnostics (Basel). 2022 Jul 23;12(8):1787. doi: 10.3390/diagnostics12081787.
2
A comparative study of hepatic steatosis using two different qualitative ultrasound techniques measured based on magnetic resonance imaging-derived proton density fat fraction.一项基于磁共振成像衍生的质子密度脂肪分数,使用两种不同定性超声技术测量肝脂肪变性的比较研究。
Hepatol Res. 2024 Jul;54(7):638-654. doi: 10.1111/hepr.14019. Epub 2024 Jan 31.
3
Toward acquisition protocol standardization for estimating liver fat content using ultrasound attenuation coefficient imaging.迈向使用超声衰减系数成像估计肝脏脂肪含量的采集协议标准化。
Ultrasonography. 2023 Jul;42(3):446-456. doi: 10.14366/usg.23014. Epub 2023 Mar 27.
4
Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis.用于量化肝脏脂肪变性的受控衰减参数(CAP)的观察者间可重复性。
Hepatol Int. 2014 Oct;8(4):576-81. doi: 10.1007/s12072-014-9573-1. Epub 2014 Sep 20.
5
Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens).使用超声控制衰减参数(Echosens)定量评估肝脏脂肪变性。
J Med Ultrason (2001). 2021 Oct;48(4):489-495. doi: 10.1007/s10396-021-01106-1. Epub 2021 Jun 16.
6
Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter.M 探头基于受控衰减参数诊断脂肪肝的有效性标准。
J Hepatol. 2017 Sep;67(3):577-584. doi: 10.1016/j.jhep.2017.05.005. Epub 2017 May 12.
7
Ultrasound-Guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method.超声引导衰减参数(UGAP)用于定量肝脂肪变性,以受控衰减参数(CAP)作为参考方法。
Med Ultrason. 2021 Feb 18;23(1):7-14. doi: 10.11152/mu-2688. Epub 2020 Oct 8.
8
The diagnostic value of novel ultrasound attenuation analysis in detecting liver steatosis identified by the controlled attenuation parameter: a diagnostic accuracy study.新型超声衰减分析在检测由受控衰减参数确定的肝脂肪变性中的诊断价值:一项诊断准确性研究。
Ann Transl Med. 2023 Jan 31;11(2):38. doi: 10.21037/atm-22-5821. Epub 2023 Jan 9.
9
Noninvasive assessment of liver steatosis in children: the clinical value of controlled attenuation parameter.儿童肝脏脂肪变性的无创评估:受控衰减参数的临床价值
BMC Gastroenterol. 2017 May 4;17(1):61. doi: 10.1186/s12876-017-0617-6.
10
Assessing Quality of Ultrasound Attenuation Coefficient Results for Liver Fat Quantification.评估用于肝脏脂肪定量的超声衰减系数结果的质量。
Diagnostics (Basel). 2024 Sep 29;14(19):2171. doi: 10.3390/diagnostics14192171.

引用本文的文献

1
Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study.以基于磁共振成像的质子密度脂肪分数为参考标准,比较衰减成像与受控衰减参数对肝脂肪变性的诊断性能:一项前瞻性多中心研究。
J Gastroenterol. 2025 Jun;60(6):727-737. doi: 10.1007/s00535-025-02224-0. Epub 2025 Feb 24.
2
Assessing Quality of Ultrasound Attenuation Coefficient Results for Liver Fat Quantification.评估用于肝脏脂肪定量的超声衰减系数结果的质量。
Diagnostics (Basel). 2024 Sep 29;14(19):2171. doi: 10.3390/diagnostics14192171.
3

本文引用的文献

1
US Attenuation for Liver Fat Quantification: An AIUM-RSNA QIBA Pulse-Echo Quantitative Ultrasound Initiative.美国肝脏脂肪定量衰减校正:AIUM-RSNA QIBA 脉冲回波定量超声倡议。
Radiology. 2022 Mar;302(3):495-506. doi: 10.1148/radiol.210736. Epub 2022 Jan 25.
2
Quantification of Liver Fat Content with Ultrasound: A WFUMB Position Paper.超声定量肝脏脂肪含量:WFUMB 立场文件。
Ultrasound Med Biol. 2021 Oct;47(10):2803-2820. doi: 10.1016/j.ultrasmedbio.2021.06.002. Epub 2021 Jul 18.
3
Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter (Echosens).
iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study.
iATT 基于磁共振质子密度脂肪分数对肝脂肪变程度分级的定量研究:一项多中心研究。
J Gastroenterol. 2024 Jun;59(6):504-514. doi: 10.1007/s00535-024-02096-w. Epub 2024 Mar 30.
4
The Accuracy of Ultrasound Controlled Attenuation Parameter in Diagnosing Hepatic Fat Content.超声控制衰减参数诊断肝脏脂肪含量的准确性
Hepat Med. 2023 Jun 9;15:51-61. doi: 10.2147/HMER.S411619. eCollection 2023.
5
Non-invasive evaluation of liver steatosis with imaging modalities: New techniques and applications.影像学方法对肝脂肪变的无创评估:新技术及应用。
World J Gastroenterol. 2023 May 7;29(17):2534-2550. doi: 10.3748/wjg.v29.i17.2534.
6
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future.非酒精性脂肪性肝病肝脂肪变的无创性影像学生物标志物:现状与未来。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S123-S135. doi: 10.3350/cmh.2022.0357. Epub 2022 Dec 12.
7
Ultrasound-Based Diagnostic Methods: Possible Use in Fatty Liver Disease Area.基于超声的诊断方法:在脂肪肝疾病领域的可能应用。
Diagnostics (Basel). 2022 Nov 16;12(11):2822. doi: 10.3390/diagnostics12112822.
使用超声控制衰减参数(Echosens)定量评估肝脏脂肪变性。
J Med Ultrason (2001). 2021 Oct;48(4):489-495. doi: 10.1007/s10396-021-01106-1. Epub 2021 Jun 16.
4
CAP for the detection of hepatic steatosis in clinical practice.临床实践中用于检测肝脂肪变性的受控衰减参数(CAP)
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):151-152. doi: 10.1016/S2468-1253(20)30367-8. Epub 2021 Jan 16.
5
Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis.使用 M 和 XL 探头的受控衰减参数评估肝脂肪变性:一项个体患者数据荟萃分析。
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):185-198. doi: 10.1016/S2468-1253(20)30357-5. Epub 2021 Jan 16.
6
Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort.经活检证实的非酒精性脂肪性肝病的死亡率:一项全国性队列研究的结果。
Gut. 2021 Jul;70(7):1375-1382. doi: 10.1136/gutjnl-2020-322786. Epub 2020 Oct 9.
7
Update to the Society of Radiologists in Ultrasound Liver Elastography Consensus Statement.超声弹性成像领域放射学会共识声明更新。
Radiology. 2020 Aug;296(2):263-274. doi: 10.1148/radiol.2020192437. Epub 2020 Jun 9.
8
Ultrasound-based techniques for the diagnosis of liver steatosis.基于超声的肝脂肪变性诊断技术。
World J Gastroenterol. 2019 Oct 28;25(40):6053-6062. doi: 10.3748/wjg.v25.i40.6053.
9
New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode.利用超声 B 模式衰减系数评估肝脂肪变性的新诊断技术。
PLoS One. 2019 Aug 27;14(8):e0221548. doi: 10.1371/journal.pone.0221548. eCollection 2019.
10
Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations.肝脏超声弹性成像:医学与生物学超声世界联合会指南及建议的更新
Ultrasound Med Biol. 2018 Dec;44(12):2419-2440. doi: 10.1016/j.ultrasmedbio.2018.07.008. Epub 2018 Sep 9.